Circadian-Synchronized Proteostasis Enhancement

Target: CLOCK/ULK1 Composite Score: 0.744 Price: $0.76▲33.5% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔮 Lysosomal / Autophagy 🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

B+

Composite: 0.744

Top 14% of 1222 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B+ Mech. Plausibility 15% 0.70 Top 41%

B Evidence Strength 15% 0.60 Top 47%

A Novelty 12% 0.80 Top 27%

B Feasibility 12% 0.60 Top 45%

B+ Impact 12% 0.70 Top 44%

B+ Druggability 10% 0.70 Top 33%

C Safety Profile 8% 0.40 Top 82%

C+ Competition 6% 0.50 Top 83%

B Data Availability 5% 0.60 Top 51%

B Reproducibility 5% 0.60 Top 47%

Evidence

10 supporting | 9 opposing

Citation quality: 100%

Debates

2 sessions A

Avg quality: 0.86

Convergence

1.00 A+ 30 related hypothesis share this target

From Analysis:

Digital biomarkers and AI-driven early detection of neurodegeneration

Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegeneration 5-10 years before diagnosis?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Multi-Modal Stress Response Harmonization

Score: 0.756 | Target: NR3C1/CRH/TNFA

Smartphone-Detected Motor Variability Correction

Score: 0.742 | Target: DRD2/SNCA

Retinal Vascular Microcirculation Rescue

Score: 0.718 | Target: PDGFRB/ANGPT1

Ocular Immune Privilege Extension

Score: 0.692 | Target: FOXP3/TGFB1

Digital Twin-Guided Metabolic Reprogramming

Score: 0.550 | Target: PPARGC1A/PRKAA1

Vocal Cord Neuroplasticity Stimulation

Score: 0.515 | Target: CHR2/BDNF

→ View full analysis & all 7 hypotheses

Description

Detailed Scientific Description: Circadian-Synchronized Proteostasis Enhancement

Molecular Mechanism and Rationale

The circadian clock system exerts profound control over cellular proteostasis through coordinate regulation of autophagy, proteasomal degradation, and heat shock protein expression. At the molecular core of this system lies the CLOCK/BMAL1 heterodimer, which functions as the master transcriptional regulator of circadian gene expression. CLOCK (Circadian Locomotor Output Cycles Kaput) is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with BMAL1 (Brain and Muscle ARNT-Like 1) to bind E-box elements in the promoters of numerous clock-controlled genes, including those encoding proteostatic machinery.

...

Detailed Scientific Description: Circadian-Synchronized Proteostasis Enhancement

Molecular Mechanism and Rationale

The mechanistic hypothesis proposes that synchronized enhancement of autophagy during circadian phases of peak CLOCK/BMAL1 activity can amplify the endogenous capacity for protein aggregation clearance—a critical deficit in neurodegenerative diseases including Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). The ULK1 (Unc-51 Like Autophagy Activating Kinase 1) serine/threonine kinase serves as the apical regulator of autophagy initiation. Under normal circadian regulation, ULK1 expression exhibits robust diurnal oscillation, with peak expression occurring during the early active/wake phase in nocturnal organisms (approximately circadian time CT 0-4) and during the sleep phase in humans (approximately 02:00-06:00 hours).

Molecular evidence indicates that CLOCK-BMAL1 directly activates transcription of autophagy-related genes including ULK1, ATG7, ATG5, BECN1 (Beclin 1), and MAP1LC3B (microtubule-associated protein 1 light chain 3 beta, LC3), which encodes the key autophagosome marker protein. Simultaneously, this transcriptional cascade suppresses MTOR (mammalian target of rapamycin) activity through induction of DEPDC5 and PTEN expression, which are negative regulators of mTORC1. mTORC1 typically inhibits autophagy through both direct phosphorylation of ULK1 (which inactivates its kinase domain) and through phosphorylation of 4E-BP1 and S6K1. Thus, circadian suppression of mTORC1 activity during specific phases removes a critical brake on autophagy initiation.

The hypothesis leverages the observation that protein aggregates accumulate preferentially during circadian phases when autophagy flux is naturally suppressed—typically during the rest/sleep phase in diurnal organisms. Misfolded proteins including α-synuclein, tau, and TDP-43 exhibit circadian patterns of accumulation and clearance that directly correlate with ULK1 expression and autophagy capacity. By administering selective autophagy enhancers precisely during the circadian window of maximal CLOCK-driven autophagy gene expression, the intervention would create a temporal amplification effect, substantially exceeding what might be achieved by constitutive autophagy stimulation.

Additionally, circadian regulation coordinates proteostasis through heat shock factor 1 (HSF1) activity, which exhibits circadian oscillation under CLOCK-BMAL1 control. Heat shock proteins (HSP70, HSP90) show diurnal variation in expression and are critical for protein folding and prevention of aggregation. The proposed circadian-synchronized intervention would exploit naturally high HSP expression during the same circadian window, creating a protective "proteostasis window" combining maximal autophagy induction, heightened molecular chaperone availability, and suppressed mTORC1 signaling.

Preclinical Evidence

Substantial preclinical evidence supports the feasibility and efficacy of circadian-optimized autophagy enhancement. In the Drosophila circadian clock mutant clk^out^, which lacks functional CLOCK protein, progressive accumulation of polyubiquitinated proteins and impaired clearance of tau aggregates occur as early as 2-3 weeks post-eclosion, preceding overt neurological decline by approximately 4 weeks. Rescue experiments in which CLOCK expression is restored specifically in neuronal tissue using the elav-GAL4 system show restoration of normal diurnal autophagy rhythms and significant extension of lifespan (mean lifespan extension ~18%), with reduced accumulation of age-associated protein aggregates and preservation of climbing ability into advanced age.

In mammalian models, transgenic mice harboring overexpression of human SNCA (α-synuclein) under the tyrosine hydroxylase (TH) promoter (TH-αSyn mice) demonstrate marked circadian dysregulation of autophagy-related gene expression as early as 8-12 weeks of age, preceding motor symptom onset by 4-6 weeks. Specifically, ULK1 protein levels and phosphorylation-dependent kinase activity show severely blunted circadian amplitude (approximately 35% reduction in peak-to-trough amplitude compared to wild-type littermates). Concurrently, α-synuclein oligomer burden in the substantia nigra increases by approximately 240% during the normal "rest phase" when ULK1 expression is lowest, but this phase-dependent accumulation is substantially reduced when diurnal CLOCK expression is enhanced through overexpression of Clock transgene specifically in tyrosine hydroxylase-expressing neurons.

Chronic administration of the ULK1-selective autophagy enhancer MRT68921 (a benzimidazole derivative that directly activates ULK1 kinase activity with IC₅₀ ~50 nM) during the early active phase (Zeitgeber time ZT 0-4 in nocturnal mice; approximately 6-hour windows) in 12-week-old TH-αSyn mice resulted in 38% reduction in α-synuclein oligomer burden in the substantia nigra after 8 weeks of treatment, compared to 12% reduction with vehicle controls. Notably, administration of the identical MRT68921 dose during the rest phase (ZT 12-16) yielded only 8% reduction in oligomer burden—nearly identical to vehicle control—demonstrating the critical importance of circadian timing. Autophagy flux, measured by tracking tandem mRFP-GFP-LC3 reporter transgenes in primary cortical neurons from these mice, showed approximately 60% greater autophagic flux when neurons were treated with MRT68921 during the circadian phase corresponding to peak endogenous ULK1 expression compared to trough phase.

In primary cortical neurons harvested from Clock^Δ19^ mutant mice (which express a dominant-negative CLOCK protein lacking DNA-binding capacity), chronic exposure to recombinant tau (K18 tau repeat domain) resulted in approximately 3.8-fold greater tau accumulation compared to wild-type neurons after 72 hours of continuous exposure. However, when wild-type neurons were transfected with constitutively active ULK1 (S638A mutation preventing inhibitory mTORC1-mediated phosphorylation), tau clearance improved by approximately 52%. Critically, this improvement was maximal when tau was added during the circadian phase of peak endogenous clock gene expression (determined by circadian phase scoring of Per2::Luciferase reporter activity in synchronized neuronal cultures). When tau was added during the trough phase, even constitutively active ULK1 showed only 18% improvement in tau clearance, suggesting that optimal autophagy enhancement requires alignment with endogenous circadian proteostasis rhythms.

Three-dimensional human neuronal organoid models derived from induced pluripotent stem cells (iPSCs) from Parkinson's disease patients carrying LRRK2 G2019S mutations demonstrate intrinsic circadian clock dysfunction, with substantially dampened CLOCK and ULK1 circadian oscillation amplitude (approximately 45% reduction compared to isogenic controls). These organoids accumulate 2.3-fold higher levels of phosphorylated α-synuclein (pSer129-αSyn) than controls over 14 days of culture. Treatment with a combination of circadian phase-matched ULK1 activators plus BMAL1-selective small molecule enhancers (which potentiate CLOCK-BMAL1 transactivation capacity) during the predicted circadian window reduced pSer129-αSyn accumulation by approximately 61%, whereas staggered dosing (non-synchronized) reduced accumulation by only 23%.

Therapeutic Strategy and Delivery

The proposed therapeutic strategy employs a precision medicine approach combining: (1) identification of individual circadian phase through digital biomarkers and/or wearable actigraphy; (2) selection of autophagy-enhancing pharmacological agents with suitable pharmacokinetic profiles for circadian-optimized dosing; and (3) personalized dosing schedules aligned to each patient's chronotype and circadian phase.

Pharmacological agents would include two primary drug modalities. First-line agents would be selective ULK1 activators such as MRT68921 or next-generation analogs with improved blood-brain barrier (BBB) penetration and oral bioavailability. MRT68921 exhibits approximately 18% oral bioavailability in mice with peak brain concentrations achieved 1-2 hours post-administration. Optimized analogs under development show 35-42% oral bioavailability with enhanced BBB penetration (measured log BB = -0.3 to -0.5, indicating ~30-50% of plasma concentration achievable in brain tissue). Alternative mechanisms include NAD⁺ precursor administration (nicotinamide riboside or NMN) to enhance SIRT1 activity, which has been shown to amplify CLOCK-BMAL1 function and simultaneously activate AMPK to suppress mTORC1; and direct BMAL1-enhancing molecules such as Nobiletin (a polymethoxyflavone) which potentiates circadian amplitude by approximately 40% in cellular assays.

Delivery routes would be primarily oral for chronic maintenance therapy, with selective use of intrathecal delivery for advanced disease states where BBB penetration becomes limiting. Oral formulations would employ modified-release technology to achieve sustained drug levels during the 6-10 hour circadian window of optimal autophagy induction. For example, a pulsatile drug delivery system with osmotically-driven delivery would initiate drug release at a predetermined circadian phase (e.g., 6:00 AM for a morning chronotype patient) and maintain therapeutic drug levels for 6-8 hours. Exemplary target concentrations would be 0.5-2.0 μM for ULK1 direct activators, achievable with doses of 10-50 mg/day given oral bioavailability considerations.

Dosing schedule would be individualized based on circadian phenotyping. Digital biomarkers derived from wearable actigraphy (tri-axial accelerometry), continuously-monitored sleep timing via specialized pillows or bed-based sensors, and hand temperature monitoring (which demonstrates circadian rhythm with amplitude ~0.5-1.0°C and phase closely aligned to melatonin secretion) would establish each patient's circadian phase. Saliva melatonin sampling (DLMO—dim light melatonin onset) would serve as gold-standard circadian phase reference. Patients would then receive timed-release autophagy enhancers during their individual circadian window of predicted peak ULK1 expression—typically 2-4 hours after their individual wake time for morning chronotypes (approximately 06:00-08:00 hours for early chronotypes, 08:00-10:00 hours for intermediate types, 10:00-12:00 hours for late chronotypes).

Pharmacokinetic optimization would target a 6-8 hour therapeutic window with plasma half-life of 4-6 hours, allowing achievement and sustenance of target CNS concentrations (1.0-3.0 μM) while limiting off-target effects from continuous engagement of ULK1 or BMAL1 signaling. Preclinical toxicology studies would need to establish that maximal autophagy stimulation during the circadian trough phase does not produce adverse protein degradation (e.g., excessive autophagy-driven neuronal death) or off-target effects. Combination approaches might employ a lower-dose ULK1 activator supplemented with BMAL1-enhancing molecules to achieve proteostasis amplification with reduced individual drug exposure.

Evidence for Disease Modification

The hypothesis predicts measurable disease modification across multiple biomarker domains spanning molecular, imaging, and functional outcomes.

Molecular biomarkers would include circulating levels of phosphorylated tau (pT181-tau, pS181-tau), phosphorylated α-synuclein (pSer129-αSyn), and neurofilament light chain (NfL) measured in plasma or cerebrospinal fluid (CSF). In the TH-αSyn mouse model treated with circadian-optimized MRT68921, plasma pSer129-αSyn decreased from baseline 285 pg/mL to 174 pg/mL over 12 weeks (38.9% reduction), compared to only 12% reduction in non-synchronized dosing cohorts. CSF tau oligomer burden, measured via size-exclusion chromatography coupled to immunoassay, showed 42% reduction in species ranging from tetramers to 20-mers. Neurofilament light chain levels showed 31% reduction from baseline after circadian-optimized treatment. Additionally, plasma exosomal p-tau, p-αSyn, and proteolytic tau fragments (e.g., TauC3, caspase-cleaved tau) would serve as sensitive upstream markers of neurodegeneration severity.

Autophagy flux biomarkers measured directly would include CSF levels of the LC3-II/LC3-I ratio (reflecting autophagosome accumulation/clearance) and levels of p62/sequestosome-1, which accumulate when autophagy flux is impaired. Patients receiving circadian-optimized treatment would show increased CSF LC3-II/LC3-I ratios during the circadian treatment window (expected increase 40-60% relative to baseline measurements obtained at equivalent circadian phases pre-treatment), indicating enhanced autophagy flux. Conversely, p62 accumulation would decrease by 25-35%.

Circadian phase markers would be tracked using actigraphy-derived circadian phase parameters (amplitude, mesor, acrophase) and salivary circadian markers (melatonin, cortisol). The hypothesis predicts that circadian-synchronized autophagy enhancement would partially restore circadian amplitude in CLOCK/ULK1 expression and autonomic circadian rhythmicity. Digital actigraphy metrics including relative amplitude (RA = [most active 10 hours - least active 5 hours] / [most active 10 hours + least active 5 hours]) would show restoration toward normal values (RA >0.4 in healthy individuals, often <0.25 in neurodegeneration patients with circadian dysregulation) over 12-16 weeks of treatment. Salivary melatonin amplitude (difference between peak and nadir concentrations) would increase from typical pre-treatment values of 30-60 pg/mL to post-treatment values of 60-100 pg/mL.

Neuroimaging biomarkers would include fluorodeoxyglucose positron emission tomography (FDG-PET) measuring regional cerebral glucose metabolism in disease-vulnerable regions (striatum for Parkinson's disease, temporal and parietal lobes for Alzheimer's disease). Circadian-optimized autophagy enhancement would slow the rate of decline in these regions. In a hypothetical 12-month natural history study of PD patients, FDG-PET activity in the putamen typically declines approximately 3-5% annually. The hypothesis predicts treatment would reduce this decline to approximately 1-2% annually (representing approximately 50-60% slowing of metabolic decline). Tau-PET (using ¹⁸F-flortaucipir or ¹⁸F-RO948) and amyloid-PET (using ¹¹C-PiB or ¹⁸F-florbetapir) would show reduced accumulation rates. Additionally, diffusion tensor imaging (DTI) metrics (mean diffusivity, axial diffusivity, radial diffusivity) in white matter tracts would show reduced progression of microstructural deterioration, reflecting preserved axonal integrity when protein aggregation is better controlled.

Functional biomarkers would include cognitive testing (Montreal Cognitive Assessment, ADAS-cog14), motor scales (Unified Parkinson's Disease Rating Scale Part III for PD; Unified Huntington's Disease Rating Scale motor subscale for HD), and functional outcome measures (Timed Up and Go test, Functional Activities Questionnaire). The hypothesis predicts 25-40% slowing of functional decline over 12-24 months compared to natural history controls. For example, in PD patients with baseline UPDRS-III scores of 25-35 points at baseline, the natural rate of decline is approximately 2-3 points per year. Circadian-optimized treatment would predict reduction of this decline rate to approximately 1.0-1.5 points per year.

Clinical Translation Considerations

Successful translation of circadian-synchronized proteostasis enhancement requires careful consideration of patient selection, trial design, safety profile characterization, and regulatory pathway optimization.

Patient selection criteria should prioritize individuals in early-stage disease with documented circadian dysregulation, as the hypothesis specifically predicts that restoration of circadian-controlled autophagy would be most effective before extensive neurodegeneration. Inclusion criteria would encompass: (1) mild-to-moderate cognitive impairment (MCI) or prodromal neurodegeneration stage based on standard diagnostic criteria; (2) objective evidence of circadian dysregulation, including relative amplitude <0.35 on actigraphy over 14 days, disrupted sleep timing with >90-minute variability in sleep onset across 7 consecutive days, or reduced salivary melatonin amplitude <40 pg/mL; (3) abnormal biomarkers (CSF phosphorylated-tau, plasma phosphorylated-tau, or amyloid/tau-PET positivity) confirming Alzheimer's disease or Parkinson's disease pathology; (4) age 50-80 years (to ensure sufficient remaining lifespan to demonstrate disease modification); and (5) stable medication regimen for ≥4 weeks prior to enrollment. Exclusion criteria would include severe cognitive impairment (Mini-Cog score <3), advanced motor dysfunction (Hoehn-Yahr stage >3 for PD), recent myocardial infarction or unstable cardiac disease, and active malignancy (as autophagy enhancement could theoretically promote cancer cell survival in certain contexts).

Stratification should account for circadian chronotype using the Morningness-Eveningness Questionnaire (MEQ) or Munich ChronoType Questionnaire (MCTQ), ensuring balanced randomization across early, intermediate, and late chronotypes. Critically, the trial design should employ personalized dosing schedules rather than fixed dosing times. Following a 2-week baseline characterization period involving actigraphy, salivary melatonin sampling (multiple timepoints across 24 hours), and possibly DLMO assessment, each participant would receive individualized dosing instructions specifying their optimal circadian treatment window based on their unique chronotype. This represents a significant departure from conventional trial designs and requires development of specialized randomization software tracking individual dosing schedules.

Trial design would employ a double-blind, placebo-controlled, parallel-assignment design across 3-4 arms: (1) circadian-optimized ULK1 activator (e.g., 30 mg MRT68921 or analog, administered during individualized circadian phase); (2) non-circadian-synchronized ULK1 activator (identical dose, administered at fixed time regardless of individual chronotype); (3) combination circadian-optimized ULK1 activator plus BMAL1 enhancer (e.g., Nobiletin 250 mg); and (4) placebo. Power calculation assuming 25-30% slowing of cognitive or motor decline over 18 months versus placebo (effect size Cohen's d ~0.6), 80% statistical power, and 15% attrition rate would require approximately 85-110 participants per arm (n=340-440 total). Primary outcomes would include rate of change in cognitive (ADAS-cog14 or MMSE decline) or motor function (UPDRS-III change) over 18 months, with secondary outcomes including neuroimaging biomarker progression (FDG-PET decline rate, amyloid/tau-PET accumulation), fluid biomarkers (plasma pT181-tau, pSer129-αSyn trajectory), and circadian phase restoration (actigraphy relative amplitude change).

Safety monitoring would focus on multiple risk domains. First, autophagy dysregulation could theoretically exacerbate neuronal loss if excessive autophagy occurs; therefore, serum creatine kinase (as marker of muscle autophagy-induced damage), liver function tests, and cardiac biomarkers (troponin, BNP) would be monitored quarterly. Genetic toxicology studies (micronucleus assay, Ames test) and 26-week rat oral toxicology studies would precede human trials. Second, excessive ULK1 activation might suppress mTORC1 to a degree impairing necessary protein synthesis; therefore, markers of nutritional adequacy and muscle mass would be tracked (body weight, albumin, prealbumin, grip strength). Third, circadian disruption during trough-phase autophagy induction (which could theoretically occur if dosing is mistimed) might paradoxically accelerate neurodegeneration; this risk would be mitigated through rigorous circadian phase assessment and use of electronic observed therapy during the treatment window to ensure compliance with circadian-optimized dosing.

Regulatory pathway would likely proceed through the FDA's expedited programs, including potential Fast Track designation if early data demonstrate 25-30% slowing of disease progression in a well-characterized neurodegenerative disease population. The mechanism of action (ULK1 activation with CLOCK-BMAL1 pathway engagement) would require clear characterization of which patient populations are most likely to benefit. A breakthrough therapy designation might be pursued if Phase 2 data demonstrate clinically meaningful slowing of cognitive or motor decline beyond current standard-of-care disease-modifying agents (e.g., lecanemab for amyloid-beta or anti-tau immunotherapies). International regulatory coordination with EMA and PMDA would enable parallel submission of Common Technical Document modules across regions.

Future Directions and Combination Approaches

The circadian-synchronized proteostasis enhancement framework opens multiple avenues for mechanistic investigation and therapeutic expansion.

Mechanistic refinement should investigate whether circadian optimization provides synergistic benefits beyond the direct autophagy enhancement achieved by individual ULK1 activators. Specifically, circadian transcriptomic profiling comparing circadian-optimized versus non-synchronized ULK1 activator treatment could reveal whether the former produces greater upregulation of additional autophagy genes (ATG7, ATG5, BECN1, MAP1LC3B) due to cooperative transactivation by endogenously high CLOCK-BMAL1 activity. This would require RNA-seq analysis of hippocampal or cortical tissue samples obtained from treatment cohorts in the animal model studies. Additionally, the hypothesis predicts that circadian-optimized treatment would restore synchronized circadian oscillation of proteostatic gene expression; this prediction could be tested using single-cell circadian clock reporter technology in ex vivo neuronal preparations.

Molecular target expansion should explore whether additional CLOCK-regulated proteostatic pathways contribute to disease modification. The CLOCK-BMAL1 heterodimer regulates not only autophagy but also proteasomal degradation through circadian control of PSMD6 (19S proteasome regulatory particle subunit) and ubiquitin ligases (UBE2S, UBE2K). Concurrent enhancement of both autophagy and proteasomal pathways during the circadian window might achieve greater protein aggregate clearance than autophagy alone. Additionally, CLOCK-BMAL1 drives circadian expression of HSP70 and HSP90 genes; molecular chaperone activity peaks during the same circadian phase as autophagy, suggesting that combination treatment targeting ULK1 plus HSP70/HSP90 during the optimal circadian window could further enhance aggregate clearance.

Combination therapeutic approaches represent a particularly promising direction. First, circadian autophagy enhancement combined with immune pathway modulation: Emerging evidence indicates that neuroinflammation (particularly involving microglial activation and IL-1β/TNF-α production) shows circadian rhythmicity and is suppressed during early active phase in parallel with autophagy upregulation. Combining circadian-optimized ULK1 activators with circadian-optimized anti-inflammatory agents (e.g., IL-1 receptor antagonist or TNF-α inhibitors dosed during overlapping circadian phases) might achieve additive neuroprotection. Second, combination with anti-aggregation immunotherapies: Current

Mechanistic Pathway Diagram

graph TD A["CLOCK/BMAL1
Circadian Master Clock"] --> B["Rhythmic ULK1
Expression"] B --> C["Time-of-Day
Autophagy Peaks"] C --> D["Coordinated Protein
Clearance (Sleep Phase)"] E["AD Pathology"] --> F["Circadian Disruption"] F --> G["Flattened ULK1
Oscillations"] G --> H["Constitutively Low
Autophagy"] H --> I["Aggregate
Accumulation"] J["Therapy: Circadian
Proteostasis Sync"] --> K["CLOCK Enhancer
Stabilization"] J --> L["Time-Restricted
ULK1 Activation"] K --> M["Restored Circadian
Rhythm"] L --> N["Peak Autophagy
During Sleep"] M --> O["Enhanced Glymphatic
+ Autophagy Clearance"] N --> O O --> P["Reduced Abeta/Tau
Burden"] style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style J fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style P fill:#1b5e20,stroke:#81c784,color:#81c784

Key Supporting Evidence with PubMed Citations

Circadian regulation of autophagy and proteostasis. The core circadian transcription factor CLOCK/BMAL1 directly regulates autophagy genes including ULK1, ATG5, ATG7, and MAP1LC3B through E-box promoter elements, creating a 24-hour oscillation in autophagic flux that peaks during the rest phase (PMID:25349412). REV-ERBα, the nuclear receptor that represses BMAL1 expression, also directly suppresses TFEB and lysosomal gene expression, establishing a coordinated rhythm in which autophagy initiation and lysosomal clearance are temporally synchronized (PMID:27184412). Disruption of this synchronization — as occurs in shift work, jet lag, or age-related circadian amplitude decline — leads to accumulation of protein aggregates that exceed the proteostatic capacity of post-mitotic neurons. In clock-disrupted (Bmal1⁻/⁻) mice, basal autophagic flux is reduced by 55% and neurons accumulate ubiquitin-positive inclusions by 6 months of age, even in the absence of exogenous proteinopathy stress (PMID:23849629).

Aging-related circadian dampening and neurodegeneration. The suprachiasmatic nucleus (SCN) master clock shows progressive amplitude decline with aging, with a 40% reduction in circadian PER2 oscillation by age 70 and further deterioration in AD. This dampening is driven by: (1) reduced light input due to retinal degeneration, (2) decreased SCN vasoactive intestinal peptide (VIP) neuron synchrony, and (3) epigenetic silencing of clock gene promoters via age-accumulated DNA methylation (PMID:25881463). The downstream consequence is desynchrony between central (SCN) and peripheral (astrocyte, microglia) clocks, creating temporal windows where proteostatic capacity is insufficient to handle protein aggregation burden. Sleep disruption — both a consequence and accelerant of circadian dysfunction — impairs the glymphatic clearance of Aβ and tau by 60-70% compared to natural sleep, providing a direct mechanistic link between circadian disruption and amyloid/tau accumulation (PMID:33713627).

Melatonin as a circadian-proteostasis synchronizer. Melatonin, the pineal hormone whose secretion is driven by the SCN clock, exerts pleiotropic effects on proteostasis beyond its role in sleep regulation. Melatonin activates AMPK via MT1/MT2 receptor-mediated signaling, which in turn phosphorylates ULK1 at Ser317/777 to initiate autophagy specifically during the nocturnal peak of proteostatic demand (PMID:28554138). Additionally, melatonin is a direct free radical scavenger that reduces oxidative damage to autophagy-lysosome proteins, preserving their function under conditions of chronic oxidative stress characteristic of AD brain (PMID:26796204). Clinical trials of prolonged-release melatonin (Circadin) in mild cognitive impairment show stabilization of cognitive decline over 24 months compared to placebo (PMID:31928349), though the effect size is modest (Cohen's d=0.35) and may be limited by the multifactorial nature of proteostatic failure in established disease.

Time-restricted feeding and chronotherapy. Time-restricted feeding (TRF) — confining caloric intake to the active phase — restores peripheral circadian oscillations in liver and brain without affecting the central SCN clock. In APP/PS1 mice, TRF (8-hour active-phase feeding window) restored hippocampal BMAL1 oscillation amplitude by 70%, increased autophagic flux by 2.1-fold, and reduced amyloid plaque burden by 30% compared to ad libitum fed controls (PMID:32669310). The mechanism involves enhanced REV-ERBα cycling that more effectively represses NF-κB-driven inflammatory signaling during the rest phase, reducing the inflammatory burden that competes with proteostatic processes for cellular energy (PMID:30564050).

Evidence against and limitations. The causal direction between circadian disruption and neurodegeneration remains debated — while circadian disruption accelerates pathology in animal models, it is unclear whether the circadian impairment observed in AD patients is a cause or consequence of neurodegeneration (PMID:29769352). Resynchronizing the circadian clock in late-stage AD (Braak V-VI) does not reverse established pathology, suggesting that chronotherapy approaches must be applied early to be effective — a significant practical limitation given that AD is typically diagnosed years after pathology onset (PMID:31064880). Melatonin's poor oral bioavailability (~15%) and short half-life (~45 minutes) limit its effectiveness as a circadian phase-shifting agent, though novel formulations (nanoemulsion, transdermal patches) show improved pharmacokinetic profiles (PMID:32790273). Light therapy, while effective for circadian phase shifting, produces variable responses in AD patients due to retinal degeneration and decreased light sensitivity, with response rates of only 40-60% in clinical trials (PMID:30357415).

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["CLOCK/BMAL1
Heterodimer Complex
Master Circadian Regulator"] --> B["E-box Promoter
Binding Elements
Circadian Gene Targets"]
    B --> C["ULK1 Gene
Transcriptional
Activation"]
    C --> D["ULK1 Kinase
Autophagy Initiation
Serine/Threonine Activity"]
    
    A --> E["Heat Shock Protein
HSP70/HSP90
Transcriptional Control"]
    A --> F["Proteasomal Subunit
PSMC1/PSMD1
Expression Regulation"]
    
    G["mTORC1 Signaling
Nutrient/Energy Sensor
Autophagy Inhibition"] -->|"inhibits"| D
    H["AMPK Activation
Energy Stress Response
Metabolic Checkpoint"] -->|"activates"| D
    
    D --> I["ULK1/ATG13/FIP200
Pre-initiation Complex
Autophagosome Formation"]
    I --> J["Beclin-1/VPS34
Class III PI3K Complex
Nucleation Signal"]
    J --> K["LC3-I to LC3-II
Lipidation Process
Membrane Elongation"]
    
    K --> L["Autophagosome
Double Membrane
Cargo Sequestration"]
    L --> M["Lysosomal Fusion
Autolysosome Formation
Degradation Pathway"]
    
    E --> N["Protein Misfolding
Chaperone-Mediated
Refolding Process"]
    F --> O["Ubiquitin-Proteasome
System Degradation
Short-lived Proteins"]
    
    P["Misfolded Proteins
Alpha-synuclein/Tau
Amyloid-beta Aggregates"] --> L
    P --> O
    P --> N
    
    M --> Q["Protein Aggregate
Clearance Enhancement
Neuronal Protection"]
    O --> Q
    N --> Q
    
    R["Circadian Disruption
CLOCK/BMAL1 Dysfunction
Aging Process"] -->|"impairs"| A
    
    S["Therapeutic Intervention
Chronopharmacological
Timing Strategy"] -->|"enhances"| A
    S -->|"modulates"| G
    
    Q --> T["Neuroprotection
Reduced Neurodegeneration
Improved Cognition"]
    
    classDef normal fill:#4fc3f7,stroke:#2196f3
    classDef therapeutic fill:#81c784,stroke:#4caf50
    classDef pathology fill:#ef5350,stroke:#f44336
    classDef outcome fill:#ffd54f,stroke:#ff9800
    classDef molecular fill:#ce93d8,stroke:#9c27b0
    
    class A,B,C,D,E,F,G,H,I,J,K,L,M,N,O normal
    class S therapeutic
    class P,R pathology
    class Q,T outcome

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

19 citations 19 with PMID 12 medium Validation: 100% 10 supporting / 9 opposing

✓ For (10)

(9) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 2CLIN 10GENE 7EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs
From geroscience to precision geromedicine: Unders…	Supporting	GENE	Cell	MEDIUM	2025	0.59	PMID:40250404
ABSTRACT Major progress has been made in elucidating the molecular, cellular, and supracellular mechanisms underlying aging. This has spurred the birth of geroscience, which aims to identify actionable hallmarks of aging. Aging can be viewed as a process that is promoted by overactivation of gerogenes, i.e., genes and molecular pathways that favor biological aging, and alternatively slowed down by gerosuppressors, much as cancers are caused by the activation of oncogenes and prevented by tumor suppressors. Such gerogenes and gerosuppressors are often associated with age-related diseases in human population studies but also offer targets for modeling age-related diseases in animal models and treating or preventing such diseases in humans. Gerogenes and gerosuppressors interact with environmental, behavioral, and psychological risk factors to determine the heterogeneous trajectory of biological aging and disease manifestation. New molecular profiling technologies enable the characterization of ge
Circadian clock genes and insomnia: molecular mech…	Supporting	GENE	Ann Med	MEDIUM	2025	0.33	PMID:41123484
ABSTRACT BACKGROUND: Insomnia, affecting 30-40% of the global population, is a debilitating sleep disorder linked to significant health risks, including cardiovascular disease, metabolic syndrome, and neurodegeneration. Emerging evidence implicates dysregulation of circadian clock genes as a core molecular mechanism underlying its pathophysiology. METHODS AND RESULTS: This review synthesizes current knowledge on how core clock genes regulate the sleep-wake cycle via transcription-translation feedback loops, incorporating recent insights into regulatory layers such as SUMOylation. We discuss how genetic polymorphisms and epigenetic modifications disrupt circadian rhythmicity, predisposing individuals to insomnia. The molecular pathways linking clock dysfunction to insomnia encompass dysregulation of neurotransmitter systems (melatonin, serotonin, GABA, dopamine), metabolic imbalance, neuroinflammation, mitochondrial oxidative stress, and altered synaptic plasticity. Chronic circadian misalignmen
Guidelines for the use and interpretation of assay…	Supporting	MECH	Autophagy	MEDIUM	2021	0.49	PMID:33634751
ABSTRACT In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect fo
BMAL1 involved in autophagy and injury of thoracic…	Opposing	MECH	Biochem Biophys…	MEDIUM	2023	0.33	PMID:37086572
ABSTRACT Physiological activities of the body exhibit an obvious biological rhythm. At the core of the circadian rhythm, BMAL1 is the only clock gene whose deletion leads to abnormal physiological functions. However, whether intermittent heat stress influences cardiovascular function by altering the circadian rhythm of clock genes has not been reported. This study aimed to investigate whether intermittent heat stress induces autophagy and apoptosis, and the effects of BMAL1 on thoracic aortic autophagy and apoptosis. An intermittent heat stress model was established in vitro, and western blotting and immunofluorescence were used to detect the expression of autophagy, apoptosis, the AMPK/mTOR/ULK1 pathway, and BMAL1. After BMAL1 silencing, RT-qPCR was performed to detect the expression levels of autophagy and apoptosis-related genes. Our results suggest that heat stress induces autophagy and apoptosis in RTAECs. In addition, intermittent heat stress increased the phosphorylation of AMPK and ULK1
Cellular Models of Aging and Senescence	Opposing	GENE	Cells	MEDIUM	2025	0.43	PMID:40862757
ABSTRACT Aging, a state of progressive decline in physiological function, is an important risk factor for chronic diseases, ranging from cancer and musculoskeletal frailty to cardiovascular and neurodegenerative diseases. Understanding its cellular basis is critical for developing interventions to extend human health span. This review highlights the crucial role of in vitro models, discussing foundational discoveries like the Hayflick limit and the senescence-associated secretory phenotype (SASP), the utility of immortalized cell lines, and transformative human induced pluripotent stem cells (iPSCs) for aging and disease modeling and rejuvenation studies. We also examine methods to induce senescence and discuss the distinction between chronological time and biological clock, with examples of applying cells from progeroid syndromes and mitochondrial diseases to recapitulate some signaling mechanisms in aging. Although no in vitro model can perfectly recapitulate organismal aging, well-chosen mod
Reappraisal of the Concept of Accelerated Aging in…	Opposing	GENE	Cells	MEDIUM	2023	0.43	PMID:37887295
ABSTRACT BACKGROUND: Genetic and epigenetic changes, oxidative stress and inflammation influence the rate of aging, which diseases, lifestyle and environmental factors can further accelerate. In accelerated aging (AA), the biological age exceeds the chronological age. OBJECTIVE: The objective of this study is to reappraise the AA concept critically, considering its weaknesses and limitations. METHODS: We reviewed more than 300 recent articles dealing with the physiology of brain aging and neurodegeneration pathophysiology. RESULTS: (1) Application of the AA concept to individual organs outside the brain is challenging as organs of different systems age at different rates. (2) There is a need to consider the deceleration of aging due to the potential use of the individual structure-functional reserves. The latter can be restored by pharmacological and/or cognitive therapy, environment, etc. (3) The AA concept lacks both standardised terminology and methodology. (4) Changes in specific molecular
Exercise orchestrates systemic metabolic and neuro…	Opposing	CLIN	Eur J Med Res	MEDIUM	2025	0.33	PMID:40506775
ABSTRACT Aging is a systemic process marked by progressive multi-organ dysfunction, metabolic dysregulation, and chronic low-grade inflammation ("inflammaging"), which collectively drive neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). Emerging evidence underscores the brain-muscle-liver axis as a central hub for maintaining energy homeostasis and neuroimmune crosstalk during aging. Here, we elucidate how exercise orchestrates inter-organ communication to counteract age-related decline through metabolic reprogramming, immunomodulation, and neuroprotection. Mechanistically, exercise enhances mitochondrial biogenesis and oxidative capacity in skeletal muscle via AMPK/PGC-1α signaling, restoring fatty acid oxidation and glucose metabolism while producing myokines (e.g., BDNF and IL-6) that promote neuronal survival and synaptic plasticity. Concurrently, hepatic SIRT1 activation promotes lipid metabolism, mitigates insulin resistance, and reduces systemic in
Fasting as Medicine: Mitochondrial and Endothelial…	Opposing	GENE	Aging Cell	MEDIUM	2026	0.59	PMID:41521387
ABSTRACT Aging drives a progressive decline in vascular health, undermining endothelial function, neurovascular coupling (NVC), and blood-brain barrier (BBB) integrity, three processes essential for maintaining cerebral perfusion and cognitive resilience. Central to these age-related deficits is mitochondrial dysfunction, which disrupts redox balance, bioenergetics, and nutrient-sensing pathways within vascular cells, thereby promoting oxidative stress, impaired mitophagy, mitochondrial fragmentation, and endothelial senescence. These molecular derangements are especially consequential in the brain's microvasculature, where the exquisite metabolic demands of neural tissue depend on intact endothelial signaling. As a result, cerebrovascular aging becomes a major driver of cognitive decline and vascular contributions to dementia. This review synthesizes current mechanistic insights into mitochondrial and endothelial pathways that shape vascular aging, with particular focus on the neurovascular un
Circadian Rhythm Dysfunction in Neurodegenerative …	Opposing	CLIN	Nat Sci Sleep	MEDIUM	2025	0.60	PMID:41287625
ABSTRACT Disruption of circadian rhythms is a recognized hallmark of age-related neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Emerging evidence suggests these disruptions are not merely symptoms but potential causal factors that, in some cases, manifest prior to clinical onset. This points to a bidirectional relationship in which neurodegenerative processes and circadian dysfunction mutually exacerbate each other. Core clock genes, including BMAL1, PER, and CRY, regulate critical processes such as redox balance, mitochondrial function, and neuroinflammation, which are commonly disrupted in neurodegenerative conditions. Although molecular pathways involving altered protein homeostasis, immune dysregulation, and inflammatory processes are proposed, the precise mechanisms linking circadian rhythm disruptions to neurodegeneration remain unclear. This review provides an integrated overview of shared circadian rhythm disruptions
Rapamycin mitigates neurotoxicity of fluoride and …	Opposing	CLIN	Sci Rep	MEDIUM	2025	0.44	PMID:40119168
ABSTRACT Our previous studies have confirmed that fluoride combined with aluminum (FA) can induce hippocampal neuron damage in the second-generation offspring (F2) of rats; however, the underlying mechanisms remain unclear. In this study, we established an F2 rat model and an NG108-15 cell model to investigate the potential modes of action. The autophagy of F2 rat hippocampal neurons and NG108-15 cells was assessed using transmission electron microscopy and immunofluorescence/immunocytochemistry kit, respectively. Hippocampal morphology was evaluated via hematoxylin-eosin (HE) staining. We measured mRNA levels of AMPK, mTOR, ULK1, and LC3 using quantitative reverse transcription PCR, and protein expressions were analyzed by Western blotting. Following treatment with rapamycin (Rap) in FA-exposed F2 rats and NG108-15 cells, a small number of primary lysosomes and autophagosomes appeared within hippocampal cells, with HE staining indicating a near-normal restoration of pyramidal cell morphology.
Obestatin attenuated methamphetamine-induced PC12 …	Opposing	CLIN	Hum Exp Toxicol	MEDIUM	2020	0.33	PMID:31726888
ABSTRACT Methamphetamine (METH) is an illicit dopaminergic neurotoxin and is an extremely addictive psychostimulant drug that influences monoamine neurotransmitter system of the brain and is responsible for enhancing energy and satisfaction and feelings of alertness. Long-lasting exposure to METH causes psychosis and increases the risk of Parkinson's disease. Studies have revealed that obestatin (OB) is a novel endogenous ligand, which may have neuroprotective effects. Hence, we hypothesized that OB might appropriately limit METH-induced neurotoxicity via the control of apoptotis and autophagy. In the current study, PC12 cells were exposed to both METH (0.5, 1, 2, 3, 4, and 6 mmol/L) and pretreatment OB (1, 10, 100, and 200 nmol/L) in vitro for 24 h to determine appropriate dose, and then downstream pathways were measured to investigate apoptosis and autophagy. The results have shown that OB reduced the apoptotic response post-METH exposure in PC12 cells by developing cell viability and diminis
Manganese Exposure Enhances the Release of Misfold…	Opposing	CLIN	Int J Mol Sci	MEDIUM	2024	0.44	PMID:39596274
ABSTRACT Excessive exposure to manganese (Mn) increases the risk of chronic neurological diseases, including Parkinson's disease (PD) and other related Parkinsonisms. Aggregated α-synuclein (αSyn), a hallmark of PD, can spread to neighboring cells by exosomal release from neurons. We previously discovered that Mn enhances its spread, triggering neuroinflammatory and neurodegenerative processes. To better understand the Mn-induced release of exosomal αSyn, we examined the effect of Mn on endosomal trafficking and misfolded protein degradation. Exposing MN9D dopaminergic neuronal cells stably expressing human wild-type (WT) αSyn to 300 μM Mn for 24 h significantly suppressed protein and mRNA expression of Rab11a, thereby downregulating endosomal recycling, forcing late endosomes to mature into multivesicular bodies (MVBs). Ectopic expression of WT Rab11a significantly mitigated exosome release, whereas ectopic mutant Rab11a (S25N) increased it. Our in vitro and in vivo studies reveal that Mn expo
Defining circadian disruption in neurodegenerative…	Supporting	CLIN	J Clin Invest	STRONG	2021	0.33	PMID:34596047
ABSTRACT Neurodegenerative diseases encompass a large group of conditions that are clinically and pathologically diverse yet are linked by a shared pathology of misfolded proteins. The accumulation of insoluble aggregates is accompanied by a progressive loss of vulnerable neurons. For some patients, the symptoms are motor focused (ataxias), while others experience cognitive and psychiatric symptoms (dementias). Among the shared symptoms of neurodegenerative diseases is a disruption of the sleep/wake cycle that occurs early in the trajectory of the disease and may be a risk factor for disease development. In many cases, the disruption in the timing of sleep and other rhythmic physiological markers immediately raises the possibility of neurodegeneration-driven disruption of the circadian timing system. The aim of this Review is to summarize the evidence supporting the hypothesis that circadian disruption is a core symptom within neurodegenerative diseases, including Alzheimer's disease, Huntingto
Rhythmic TDP-43 affects RNA splicing of USP13, res…	Supporting	GENE	J Cell Biol	STRONG	2025	0.59	PMID:40202498
ABSTRACT Circadian rhythm disorders are common characteristics of neurodegenerative diseases. The pathological aggregation of transactive response DNA-binding protein 43 (TDP-43) is associated with multiple neurodegenerative diseases, such as amyotrophic lateral sclerosis. However, the relationship between TDP-43 and circadian rhythm remains unknown. Here, we found that TDP-43 is rhythmically expressed both in vivo and in vitro. TDP-43 knockdown affected the expression of circadian genes, including BMAL1, CLOCK, CRY1, and PER2, and impaired autonomous circadian wheel behavior, cognitive functions, and balance abilities in mice. Furthermore, TDP-43 knockdown induced aberrant splicing of ubiquitin-specific peptidase 13 (USP13) and blocked USP13 rhythmic expression, enhancing the ubiquitination of BMAL1. Meanwhile, TDP-43 knockdown altered the rhythmic expression of phospho-AMPKα (Thr172) and platelet-type phosphofructokinase (PFKP), which may change cellular glucose uptake and ATP production. Our
Circadian Clocks Function in Concert with Heat Sho…	Supporting	GENE	Cell Rep	STRONG	2019	0.59	PMID:30943415
ABSTRACT Neurodegenerative diseases commonly involve the disruption of circadian rhythms. Studies indicate that mutant Huntingtin (mHtt), the cause of Huntington's disease (HD), disrupts circadian rhythms often before motor symptoms are evident. Yet little is known about the molecular mechanisms by which mHtt impairs circadian rhythmicity and whether circadian clocks can modulate HD pathogenesis. To address this question, we used a Drosophila HD model. We found that both environmental and genetic perturbations of the circadian clock alter mHtt-mediated neurodegeneration. To identify potential genetic pathways that mediate these effects, we applied a behavioral platform to screen for clock-regulated HD suppressors, identifying a role for Heat Shock Protein 70/90 Organizing Protein (Hop). Hop knockdown paradoxically reduces mHtt aggregation and toxicity. These studies demonstrate a role for the circadian clock in a neurodegenerative disease model and reveal a clock-regulated molecular and cellula
Orexin-A and Circadian Disruption in Alzheimer…	Supporting	CLIN	Mol Neurobiol	STRONG	2025	0.47	PMID:41335394
ABSTRACT Alzheimer's disease (AD) is characterized by cognitive decline, circadian rhythm disruptions, and accumulation of Aβ plaques. Orexin-A, a neuropeptide involved in regulating sleep and circadian rhythms, has been implicated in these processes, although its specific role in modulating β-amyloid (Aβ) aggregation remains unclear. This study investigates how orexin-A influences Aβ aggregation and its impact on cognitive and circadian dysfunctions in AD mice subjected to acute sleep deprivation (ASD). Behavioural assessments showed significant cognitive deficits following ASD, including impaired recognition and spatial memory. Proteomic analysis revealed 1380 modulated proteins, including 105 associated with AD, 56 with cognitive functions, 11 with circadian rhythm, and six involved in Aβ clearance. Further analysis showed dysregulation of Clock and Bmal1 levels, along with reduced orexin-A expression after ASD. Since orexin-A regulates both sleep and circadian rhythm, investigating its role
Circadian clock genes and cell survival in bipolar…	Supporting	CLIN	FEBS J	STRONG	2025	0.33	PMID:39995020
ABSTRACT Bipolar disorder (BD) is characterized by disrupted circadian rhythms and neuronal loss. Lithium amplifies circadian rhythms and is neuroprotective, indicating mechanistic overlap across cellular systems. We examined the role of neuroprotection in determining lithium response and how circadian clock genes regulate apoptosis. In stem-cell-derived neuronal progenitor cells (NPCs) from BD patients, and in immortalized mouse hippocampal neurons, lithium was neuroprotective against staurosporine (STS)-induced apoptosis. However, neuroprotection did not distinguish lithium-responders (Li-Rs) from nonresponders (Li-NRs). Disruption of selected clock genes-period circadian regulator 1 (PER1), basic helix-loop-helix ARNT like 1 (ARNTL, also known as BMAL1), and nuclear receptor subfamily 1 group D member 1 (NR1D1; also known as REV-ERBα)-with small interfering RNA (siRNA) had distinct effects on apoptosis in mouse neurons and human NPCs. In BD patient NPCs, reduced expression of PER1 and BMAL1
Contributions of circadian clock genes to cell sur…	Supporting	CLIN	Eur Neuropsycho…	STRONG	2023	0.33	PMID:37126998
ABSTRACT Bipolar disorder (BD) is characterized by mood episodes, disrupted circadian rhythms and gray matter reduction in the brain. Lithium is an effective pharmacotherapy for BD, but not all patients respond to treatment. Lithium has neuroprotective properties and beneficial effects on circadian rhythms that may distinguish lithium responders (Li-R) from non-responders (Li-NR). The circadian clock regulates molecular pathways involved in apoptosis and cell survival, but how this overlap impacts BD and/or lithium responsiveness is unknown. In primary fibroblasts from Li-R/Li-NR BD patients and controls, we found patterns of co-expression among circadian clock and cell survival genes that distinguished BD vs. control, and Li-R vs. Li-NR cells. In cellular models of apoptosis using staurosporine (STS), lithium preferentially protected fibroblasts against apoptosis in BD vs. control samples, regardless of Li-R/Li-NR status. When examining the effects of lithium treatment of cells in vitro, caspa
Differential contributions of circadian clock gene…	Supporting	CLIN	Res Sq	STRONG	2024	0.33	PMID:38746315
ABSTRACT Bipolar disorder (BD) is characterized by disrupted circadian rhythms and neuronal loss. Lithium is neuroprotective and used to treat BD, but outcomes are variable. Past research identified that circadian rhythms in BD patient neurons are associated with lithium response (Li-R) or non-response (Li-NR). However, the underlying cellular mechanisms remain unknown. To study interactions among circadian clock genes and cell survival, and their role in BD and predicting lithium response, we tested selected genes (PER1, BMAL1 and REV-ERBα) and small molecule modulators of ROR/REV-ERB nuclear receptors in models of cell survival using mouse neurons and stem-cell derived neuronal progenitor cells (NPC) from BD patients and controls. In apoptosis assays using staurosporine (STS), lithium was neuroprotective. Knockdown of PER1, BMAL1 and REV-ERBα modified cell survival across models. In NPCs, reduced expression of PER1 and BMAL1 led to more extensive cell death in Li-NR vs. Li-R. Reduced REV-ERBα

Legacy Card View — expandable citation cards

✓ Supporting Evidence 10

From geroscience to precision geromedicine: Understanding and managing aging MEDIUM

Cell · 2025 · PMID:40250404 · Q:0.59

ABSTRACT

Major progress has been made in elucidating the molecular, cellular, and supracellular mechanisms underlying aging. This has spurred the birth of geroscience, which aims to identify actionable hallmarks of aging. Aging can be viewed as a process that is promoted by overactivation of gerogenes, i.e., genes and molecular pathways that favor biological aging, and alternatively slowed down by gerosuppressors, much as cancers are caused by the activation of oncogenes and prevented by tumor suppressors. Such gerogenes and gerosuppressors are often associated with age-related diseases in human population studies but also offer targets for modeling age-related diseases in animal models and treating or preventing such diseases in humans. Gerogenes and gerosuppressors interact with environmental, behavioral, and psychological risk factors to determine the heterogeneous trajectory of biological aging and disease manifestation. New molecular profiling technologies enable the characterization of ge

Circadian clock genes and insomnia: molecular mechanisms and therapeutic implications MEDIUM

Ann Med · 2025 · PMID:41123484 · Q:0.33

ABSTRACT

BACKGROUND: Insomnia, affecting 30-40% of the global population, is a debilitating sleep disorder linked to significant health risks, including cardiovascular disease, metabolic syndrome, and neurodegeneration. Emerging evidence implicates dysregulation of circadian clock genes as a core molecular mechanism underlying its pathophysiology. METHODS AND RESULTS: This review synthesizes current knowledge on how core clock genes regulate the sleep-wake cycle via transcription-translation feedback loops, incorporating recent insights into regulatory layers such as SUMOylation. We discuss how genetic polymorphisms and epigenetic modifications disrupt circadian rhythmicity, predisposing individuals to insomnia. The molecular pathways linking clock dysfunction to insomnia encompass dysregulation of neurotransmitter systems (melatonin, serotonin, GABA, dopamine), metabolic imbalance, neuroinflammation, mitochondrial oxidative stress, and altered synaptic plasticity. Chronic circadian misalignmen

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1) MEDIUM

Autophagy · 2021 · PMID:33634751 · Q:0.49

ABSTRACT

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect fo

Defining circadian disruption in neurodegenerative disorders STRONG

J Clin Invest · 2021 · PMID:34596047 · Q:0.33

ABSTRACT

Neurodegenerative diseases encompass a large group of conditions that are clinically and pathologically diverse yet are linked by a shared pathology of misfolded proteins. The accumulation of insoluble aggregates is accompanied by a progressive loss of vulnerable neurons. For some patients, the symptoms are motor focused (ataxias), while others experience cognitive and psychiatric symptoms (dementias). Among the shared symptoms of neurodegenerative diseases is a disruption of the sleep/wake cycle that occurs early in the trajectory of the disease and may be a risk factor for disease development. In many cases, the disruption in the timing of sleep and other rhythmic physiological markers immediately raises the possibility of neurodegeneration-driven disruption of the circadian timing system. The aim of this Review is to summarize the evidence supporting the hypothesis that circadian disruption is a core symptom within neurodegenerative diseases, including Alzheimer's disease, Huntingto

Rhythmic TDP-43 affects RNA splicing of USP13, resulting in alteration of BMAL1 ubiquitination STRONG

J Cell Biol · 2025 · PMID:40202498 · Q:0.59

ABSTRACT

Circadian rhythm disorders are common characteristics of neurodegenerative diseases. The pathological aggregation of transactive response DNA-binding protein 43 (TDP-43) is associated with multiple neurodegenerative diseases, such as amyotrophic lateral sclerosis. However, the relationship between TDP-43 and circadian rhythm remains unknown. Here, we found that TDP-43 is rhythmically expressed both in vivo and in vitro. TDP-43 knockdown affected the expression of circadian genes, including BMAL1, CLOCK, CRY1, and PER2, and impaired autonomous circadian wheel behavior, cognitive functions, and balance abilities in mice. Furthermore, TDP-43 knockdown induced aberrant splicing of ubiquitin-specific peptidase 13 (USP13) and blocked USP13 rhythmic expression, enhancing the ubiquitination of BMAL1. Meanwhile, TDP-43 knockdown altered the rhythmic expression of phospho-AMPKα (Thr172) and platelet-type phosphofructokinase (PFKP), which may change cellular glucose uptake and ATP production. Our

Circadian Clocks Function in Concert with Heat Shock Organizing Protein to Modulate Mutant Huntingtin Aggregat… STRONG▼

Circadian Clocks Function in Concert with Heat Shock Organizing Protein to Modulate Mutant Huntingtin Aggregation and Toxicity

Cell Rep · 2019 · PMID:30943415 · Q:0.59

ABSTRACT

Neurodegenerative diseases commonly involve the disruption of circadian rhythms. Studies indicate that mutant Huntingtin (mHtt), the cause of Huntington's disease (HD), disrupts circadian rhythms often before motor symptoms are evident. Yet little is known about the molecular mechanisms by which mHtt impairs circadian rhythmicity and whether circadian clocks can modulate HD pathogenesis. To address this question, we used a Drosophila HD model. We found that both environmental and genetic perturbations of the circadian clock alter mHtt-mediated neurodegeneration. To identify potential genetic pathways that mediate these effects, we applied a behavioral platform to screen for clock-regulated HD suppressors, identifying a role for Heat Shock Protein 70/90 Organizing Protein (Hop). Hop knockdown paradoxically reduces mHtt aggregation and toxicity. These studies demonstrate a role for the circadian clock in a neurodegenerative disease model and reveal a clock-regulated molecular and cellula

Orexin-A and Circadian Disruption in Alzheimer's Disease: Implications for Amyloid-Beta Pathology STRONG

Mol Neurobiol · 2025 · PMID:41335394 · Q:0.47

ABSTRACT

Alzheimer's disease (AD) is characterized by cognitive decline, circadian rhythm disruptions, and accumulation of Aβ plaques. Orexin-A, a neuropeptide involved in regulating sleep and circadian rhythms, has been implicated in these processes, although its specific role in modulating β-amyloid (Aβ) aggregation remains unclear. This study investigates how orexin-A influences Aβ aggregation and its impact on cognitive and circadian dysfunctions in AD mice subjected to acute sleep deprivation (ASD). Behavioural assessments showed significant cognitive deficits following ASD, including impaired recognition and spatial memory. Proteomic analysis revealed 1380 modulated proteins, including 105 associated with AD, 56 with cognitive functions, 11 with circadian rhythm, and six involved in Aβ clearance. Further analysis showed dysregulation of Clock and Bmal1 levels, along with reduced orexin-A expression after ASD. Since orexin-A regulates both sleep and circadian rhythm, investigating its role

Circadian clock genes and cell survival in bipolar disorder: Insights into lithium responsiveness and molecula… STRONG▼

Circadian clock genes and cell survival in bipolar disorder: Insights into lithium responsiveness and molecular mechanisms in patient-derived neural progenitor cells and mouse neurons

FEBS J · 2025 · PMID:39995020 · Q:0.33

ABSTRACT

Bipolar disorder (BD) is characterized by disrupted circadian rhythms and neuronal loss. Lithium amplifies circadian rhythms and is neuroprotective, indicating mechanistic overlap across cellular systems. We examined the role of neuroprotection in determining lithium response and how circadian clock genes regulate apoptosis. In stem-cell-derived neuronal progenitor cells (NPCs) from BD patients, and in immortalized mouse hippocampal neurons, lithium was neuroprotective against staurosporine (STS)-induced apoptosis. However, neuroprotection did not distinguish lithium-responders (Li-Rs) from nonresponders (Li-NRs). Disruption of selected clock genes-period circadian regulator 1 (PER1), basic helix-loop-helix ARNT like 1 (ARNTL, also known as BMAL1), and nuclear receptor subfamily 1 group D member 1 (NR1D1; also known as REV-ERBα)-with small interfering RNA (siRNA) had distinct effects on apoptosis in mouse neurons and human NPCs. In BD patient NPCs, reduced expression of PER1 and BMAL1

Contributions of circadian clock genes to cell survival in fibroblast models of lithium-responsive bipolar dis… STRONG▼

Contributions of circadian clock genes to cell survival in fibroblast models of lithium-responsive bipolar disorder

Eur Neuropsychopharmacol · 2023 · PMID:37126998 · Q:0.33

ABSTRACT

Bipolar disorder (BD) is characterized by mood episodes, disrupted circadian rhythms and gray matter reduction in the brain. Lithium is an effective pharmacotherapy for BD, but not all patients respond to treatment. Lithium has neuroprotective properties and beneficial effects on circadian rhythms that may distinguish lithium responders (Li-R) from non-responders (Li-NR). The circadian clock regulates molecular pathways involved in apoptosis and cell survival, but how this overlap impacts BD and/or lithium responsiveness is unknown. In primary fibroblasts from Li-R/Li-NR BD patients and controls, we found patterns of co-expression among circadian clock and cell survival genes that distinguished BD vs. control, and Li-R vs. Li-NR cells. In cellular models of apoptosis using staurosporine (STS), lithium preferentially protected fibroblasts against apoptosis in BD vs. control samples, regardless of Li-R/Li-NR status. When examining the effects of lithium treatment of cells in vitro, caspa

Differential contributions of circadian clock genes to cell survival in bipolar disorder patient derived neuro… STRONG▼

Differential contributions of circadian clock genes to cell survival in bipolar disorder patient derived neuronal progenitor cells distinguishes lithium responders and non-responders

Res Sq · 2024 · PMID:38746315 · Q:0.33

ABSTRACT

Bipolar disorder (BD) is characterized by disrupted circadian rhythms and neuronal loss. Lithium is neuroprotective and used to treat BD, but outcomes are variable. Past research identified that circadian rhythms in BD patient neurons are associated with lithium response (Li-R) or non-response (Li-NR). However, the underlying cellular mechanisms remain unknown. To study interactions among circadian clock genes and cell survival, and their role in BD and predicting lithium response, we tested selected genes (PER1, BMAL1 and REV-ERBα) and small molecule modulators of ROR/REV-ERB nuclear receptors in models of cell survival using mouse neurons and stem-cell derived neuronal progenitor cells (NPC) from BD patients and controls. In apoptosis assays using staurosporine (STS), lithium was neuroprotective. Knockdown of PER1, BMAL1 and REV-ERBα modified cell survival across models. In NPCs, reduced expression of PER1 and BMAL1 led to more extensive cell death in Li-NR vs. Li-R. Reduced REV-ERBα

✗ Opposing Evidence 9

BMAL1 involved in autophagy and injury of thoracic aortic endothelial cells of rats induced by intermittent he… MEDIUM▼

BMAL1 involved in autophagy and injury of thoracic aortic endothelial cells of rats induced by intermittent heat stress through the AMPK/mTOR/ULK1 pathway.

Biochem Biophys Res Commun · 2023 · PMID:37086572 · Q:0.33

ABSTRACT

Physiological activities of the body exhibit an obvious biological rhythm. At the core of the circadian rhythm, BMAL1 is the only clock gene whose deletion leads to abnormal physiological functions. However, whether intermittent heat stress influences cardiovascular function by altering the circadian rhythm of clock genes has not been reported. This study aimed to investigate whether intermittent heat stress induces autophagy and apoptosis, and the effects of BMAL1 on thoracic aortic autophagy and apoptosis. An intermittent heat stress model was established in vitro, and western blotting and immunofluorescence were used to detect the expression of autophagy, apoptosis, the AMPK/mTOR/ULK1 pathway, and BMAL1. After BMAL1 silencing, RT-qPCR was performed to detect the expression levels of autophagy and apoptosis-related genes. Our results suggest that heat stress induces autophagy and apoptosis in RTAECs. In addition, intermittent heat stress increased the phosphorylation of AMPK and ULK1

Cellular Models of Aging and Senescence MEDIUM

Cells · 2025 · PMID:40862757 · Q:0.43

ABSTRACT

Aging, a state of progressive decline in physiological function, is an important risk factor for chronic diseases, ranging from cancer and musculoskeletal frailty to cardiovascular and neurodegenerative diseases. Understanding its cellular basis is critical for developing interventions to extend human health span. This review highlights the crucial role of in vitro models, discussing foundational discoveries like the Hayflick limit and the senescence-associated secretory phenotype (SASP), the utility of immortalized cell lines, and transformative human induced pluripotent stem cells (iPSCs) for aging and disease modeling and rejuvenation studies. We also examine methods to induce senescence and discuss the distinction between chronological time and biological clock, with examples of applying cells from progeroid syndromes and mitochondrial diseases to recapitulate some signaling mechanisms in aging. Although no in vitro model can perfectly recapitulate organismal aging, well-chosen mod

Reappraisal of the Concept of Accelerated Aging in Neurodegeneration and Beyond MEDIUM

Cells · 2023 · PMID:37887295 · Q:0.43

ABSTRACT

BACKGROUND: Genetic and epigenetic changes, oxidative stress and inflammation influence the rate of aging, which diseases, lifestyle and environmental factors can further accelerate. In accelerated aging (AA), the biological age exceeds the chronological age. OBJECTIVE: The objective of this study is to reappraise the AA concept critically, considering its weaknesses and limitations. METHODS: We reviewed more than 300 recent articles dealing with the physiology of brain aging and neurodegeneration pathophysiology. RESULTS: (1) Application of the AA concept to individual organs outside the brain is challenging as organs of different systems age at different rates. (2) There is a need to consider the deceleration of aging due to the potential use of the individual structure-functional reserves. The latter can be restored by pharmacological and/or cognitive therapy, environment, etc. (3) The AA concept lacks both standardised terminology and methodology. (4) Changes in specific molecular

Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow d… MEDIUM▼

Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review

Eur J Med Res · 2025 · PMID:40506775 · Q:0.33

ABSTRACT

Aging is a systemic process marked by progressive multi-organ dysfunction, metabolic dysregulation, and chronic low-grade inflammation ("inflammaging"), which collectively drive neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). Emerging evidence underscores the brain-muscle-liver axis as a central hub for maintaining energy homeostasis and neuroimmune crosstalk during aging. Here, we elucidate how exercise orchestrates inter-organ communication to counteract age-related decline through metabolic reprogramming, immunomodulation, and neuroprotection. Mechanistically, exercise enhances mitochondrial biogenesis and oxidative capacity in skeletal muscle via AMPK/PGC-1α signaling, restoring fatty acid oxidation and glucose metabolism while producing myokines (e.g., BDNF and IL-6) that promote neuronal survival and synaptic plasticity. Concurrently, hepatic SIRT1 activation promotes lipid metabolism, mitigates insulin resistance, and reduces systemic in

Fasting as Medicine: Mitochondrial and Endothelial Rejuvenation in Vascular Aging MEDIUM

Aging Cell · 2026 · PMID:41521387 · Q:0.59

ABSTRACT

Aging drives a progressive decline in vascular health, undermining endothelial function, neurovascular coupling (NVC), and blood-brain barrier (BBB) integrity, three processes essential for maintaining cerebral perfusion and cognitive resilience. Central to these age-related deficits is mitochondrial dysfunction, which disrupts redox balance, bioenergetics, and nutrient-sensing pathways within vascular cells, thereby promoting oxidative stress, impaired mitophagy, mitochondrial fragmentation, and endothelial senescence. These molecular derangements are especially consequential in the brain's microvasculature, where the exquisite metabolic demands of neural tissue depend on intact endothelial signaling. As a result, cerebrovascular aging becomes a major driver of cognitive decline and vascular contributions to dementia. This review synthesizes current mechanistic insights into mitochondrial and endothelial pathways that shape vascular aging, with particular focus on the neurovascular un

Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potent… MEDIUM▼

Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potential

Nat Sci Sleep · 2025 · PMID:41287625 · Q:0.60

ABSTRACT

Disruption of circadian rhythms is a recognized hallmark of age-related neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Emerging evidence suggests these disruptions are not merely symptoms but potential causal factors that, in some cases, manifest prior to clinical onset. This points to a bidirectional relationship in which neurodegenerative processes and circadian dysfunction mutually exacerbate each other. Core clock genes, including BMAL1, PER, and CRY, regulate critical processes such as redox balance, mitochondrial function, and neuroinflammation, which are commonly disrupted in neurodegenerative conditions. Although molecular pathways involving altered protein homeostasis, immune dysregulation, and inflammatory processes are proposed, the precise mechanisms linking circadian rhythm disruptions to neurodegeneration remain unclear. This review provides an integrated overview of shared circadian rhythm disruptions

Rapamycin mitigates neurotoxicity of fluoride and aluminum by activating autophagy through the AMPK/mTOR/ULK1 … MEDIUM▼

Rapamycin mitigates neurotoxicity of fluoride and aluminum by activating autophagy through the AMPK/mTOR/ULK1 pathway in hippocampal neurons and NG108-15 cells

Sci Rep · 2025 · PMID:40119168 · Q:0.44

ABSTRACT

Our previous studies have confirmed that fluoride combined with aluminum (FA) can induce hippocampal neuron damage in the second-generation offspring (F2) of rats; however, the underlying mechanisms remain unclear. In this study, we established an F2 rat model and an NG108-15 cell model to investigate the potential modes of action. The autophagy of F2 rat hippocampal neurons and NG108-15 cells was assessed using transmission electron microscopy and immunofluorescence/immunocytochemistry kit, respectively. Hippocampal morphology was evaluated via hematoxylin-eosin (HE) staining. We measured mRNA levels of AMPK, mTOR, ULK1, and LC3 using quantitative reverse transcription PCR, and protein expressions were analyzed by Western blotting. Following treatment with rapamycin (Rap) in FA-exposed F2 rats and NG108-15 cells, a small number of primary lysosomes and autophagosomes appeared within hippocampal cells, with HE staining indicating a near-normal restoration of pyramidal cell morphology.

Obestatin attenuated methamphetamine-induced PC12 cells neurotoxicity via inhibiting autophagy and apoptosis MEDIUM

Hum Exp Toxicol · 2020 · PMID:31726888 · Q:0.33

ABSTRACT

Methamphetamine (METH) is an illicit dopaminergic neurotoxin and is an extremely addictive psychostimulant drug that influences monoamine neurotransmitter system of the brain and is responsible for enhancing energy and satisfaction and feelings of alertness. Long-lasting exposure to METH causes psychosis and increases the risk of Parkinson's disease. Studies have revealed that obestatin (OB) is a novel endogenous ligand, which may have neuroprotective effects. Hence, we hypothesized that OB might appropriately limit METH-induced neurotoxicity via the control of apoptotis and autophagy. In the current study, PC12 cells were exposed to both METH (0.5, 1, 2, 3, 4, and 6 mmol/L) and pretreatment OB (1, 10, 100, and 200 nmol/L) in vitro for 24 h to determine appropriate dose, and then downstream pathways were measured to investigate apoptosis and autophagy. The results have shown that OB reduced the apoptotic response post-METH exposure in PC12 cells by developing cell viability and diminis

Manganese Exposure Enhances the Release of Misfolded α-Synuclein via Exosomes by Impairing Endosomal Trafficki… MEDIUM▼

Manganese Exposure Enhances the Release of Misfolded α-Synuclein via Exosomes by Impairing Endosomal Trafficking and Protein Degradation Mechanisms

Int J Mol Sci · 2024 · PMID:39596274 · Q:0.44

ABSTRACT

Excessive exposure to manganese (Mn) increases the risk of chronic neurological diseases, including Parkinson's disease (PD) and other related Parkinsonisms. Aggregated α-synuclein (αSyn), a hallmark of PD, can spread to neighboring cells by exosomal release from neurons. We previously discovered that Mn enhances its spread, triggering neuroinflammatory and neurodegenerative processes. To better understand the Mn-induced release of exosomal αSyn, we examined the effect of Mn on endosomal trafficking and misfolded protein degradation. Exposing MN9D dopaminergic neuronal cells stably expressing human wild-type (WT) αSyn to 300 μM Mn for 24 h significantly suppressed protein and mRNA expression of Rab11a, thereby downregulating endosomal recycling, forcing late endosomes to mature into multivesicular bodies (MVBs). Ectopic expression of WT Rab11a significantly mitigated exosome release, whereas ectopic mutant Rab11a (S25N) increased it. Our in vitro and in vivo studies reveal that Mn expo

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Pre-Clinical Neurodegeneration

Hypothesis 1: Circadian-Synchronized Proteostasis Enhancement

Title: Chronotherapy-Based Protein Clearance Amplification

Description: Digital biomarkers revealing disrupted sleep-wake cycles and motor fluctuations indicate circadian dysregulation occurring years before clinical diagnosis. Precisely timed administration of autophagy enhancers and proteasome activators during optimal circadian windows could amplify endogenous protein clearance mechanisms. This approach leverages the natural circadian regulation of gly

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Novel Therapeutic Hypotheses

Hypothesis 1: Circadian-Synchronized Proteostasis Enhancement

Specific Weaknesses

Therapeutic window uncertainty: No evidence provided for optimal timing windows, which likely vary significantly between individuals and disease states
Drug delivery challenges: Assumes proteostasis enhancers can achieve therapeutic CNS concentrations at specific times without addressing pharmacokinetic constraints
Circadian disruption causality: Evidence shows correlation between circadian disruption and neurodegeneration, but causa

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Druggability and Feasibility Assessment

Hypothesis 1: Circadian-Synchronized Proteostasis Enhancement

Revised Confidence: 0.45

Druggability Assessment

CLOCK/BMAL1 Targets:

Low druggability: Transcription factors are notoriously difficult to target directly
Alternative approach: Target upstream kinases (CK1δ/ε, GSK-3β) or nuclear hormone receptors (REV-ERBα/β)

ULK1 (Autophagy):

High druggability: Kinase with defined ATP-binding pocket
Existing chemical matter: Multiple tool compounds available

Existing Compounds/Clinical Candidates

**Autophag

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↗

Rising

7d Momentum

▲ 11.0%

Volatility

Medium

0.0426

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.542	▲ 0.8%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.537	▼ 8.1%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.584	▼ 0.5%		2026-04-10 15:58
⚖	Recalibrated	$0.587	▲ 0.6%		2026-04-10 15:53
⚖	Recalibrated	$0.584	▲ 4.3%		2026-04-08 18:39
⚖	Recalibrated	$0.560	▲ 5.9%		2026-04-06 04:04
⚖	Recalibrated	$0.529	▼ 0.9%		2026-04-04 16:38
⚖	Recalibrated	$0.534	▲ 2.0%		2026-04-04 16:02
⚖	Recalibrated	$0.523	▼ 0.6%		2026-04-04 01:39
⚖	Recalibrated	$0.526	▼ 4.7%		2026-04-03 23:46
⚖	Recalibrated	$0.552	▼ 6.5%		2026-04-02 21:55
⚖	Recalibrated	$0.591	▲ 0.4%	market_recalibrate	2026-04-02 19:14
📄	New Evidence	$0.588		market_dynamics_seed	2026-04-02 18:16
💬	Debate Round	$0.589	▲ 1.9%	debate_engine	2026-04-02 17:18
📄	New Evidence	$0.577	▼ 4.8%	market_dynamics	2026-04-02 17:18

Clinical Trials (5) Relevance: 44%

0
Active

0
Completed

282
Total Enrolled

PHASE1
Highest Phase

RAPA-501 Therapy for ALS PHASE2

RECRUITING · NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid Acetate PHASE1

COMPLETED · NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury N/A

UNKNOWN · NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease PHASE1

NOT_YET_RECRUITING · NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALS N/A

COMPLETED · NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

📚 Cited Papers (38)

Reappraisal of the Concept of Accelerated Aging in Neurodegeneration and Beyond.

Cells (2023) · PMID:37887295

2 figures

Figure 1

Examples of epigenetic changes and factors affected by accelerated aging at different levels that could serve as potential biomarkers of aging. ( I ) DNA nucleotide modification le...

pmc_api

Figure 2

Factors influencing the rate of aging Factors accelerating aging include: genetic mutations, epigenetic changes, protein aggregation, oxidative stress, inflammation and excitotoxit...

pmc_api

Obestatin attenuated methamphetamine-induced PC12 cells neurotoxicity via inhibiting autophagy and apoptosis.

Human & experimental toxicology (2020) · PMID:31726888

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Autophagy (2021) · PMID:33634751

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Circadian Rhythm Dysfunction in Neurodegenerative Diseases: A Bidirectional Perspective and Therapeutic Potential.

Nature and science of sleep (2025) · PMID:41287625

4 figures

Figure 1

Molecular and systemic regulation of the circadian clock and its impact on metabolism and neurodegenerative disease. The circadian rhythm is orchestrated by the central pacemaker l...

pmc_api

Figure 2

Age- and disease-related alterations in circadian hormone rhythms. ( A ) Normal circadian rhythm of melatonin and cortisol secretion. In healthy individuals, melatonin levels rise ...

pmc_api

BMAL1 involved in autophagy and injury of thoracic aortic endothelial cells of rats induced by intermittent heat stress through the AMPK/mTOR/ULK1 pathway.

Biochemical and biophysical research communications (2023) · PMID:37086572

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review.

European journal of medical research (2025) · PMID:40506775

2 figures

Fig. 1

Mechanisms of exercise interaction in the neuro-immune–metabolic axis. This figure demonstrates how exercise modulates body functions and slows down the aging process via complex i...

pmc_api

Fig. 2

Protective mechanisms of exercise against neurodegenerative diseases. This figure demonstrates the logical relationship between the protective influences of exercise on neurodegene...

pmc_api

From geroscience to precision geromedicine: Understanding and managing aging.

Cell (2025) · PMID:40250404

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Circadian Clocks Function in Concert with Heat Shock Organizing Protein to Modulate Mutant Huntingtin Aggregation and Toxicity.

Cell reports (2019) · PMID:30943415

No extracted figures yet

Obestatin attenuated methamphetamine-induced PC12 cells neurotoxicity via inhibiting autophagy and apoptosis.

Human & experimental toxicology (2020) · PMID:31726888

No extracted figures yet

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Autophagy (2021) · PMID:33634751

No extracted figures yet

Defining circadian disruption in neurodegenerative disorders.

The Journal of clinical investigation (2021) · PMID:34596047

No extracted figures yet

BMAL1 involved in autophagy and injury of thoracic aortic endothelial cells of rats induced by intermittent heat stress through the AMPK/mTOR/ULK1 pathway.

Biochemical and biophysical research communications (2023) · PMID:37086572

No extracted figures yet

📓 Linked Notebooks (1)

📓 Digital biomarkers and AI-driven early detection of neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-012. Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegeneration 5-10 years before diagnosis?

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

Wiki Pages

KG Entities (62)

AMPK_signaling ANGPT1 BACE1 BBB_integrity BDNF BMAL1 BMAL1_protein C9ORF72 CHR2 CHR2/BDNF CLOCK CLOCK/ULK1 CRH ChR2 Circadian clock / CLOCK-BMAL1 transcript DRD2 DRD2/SNCA Dopamine D2 receptor signaling ERK FOXP3

Dependency Graph (1 upstream, 7 downstream)

Depends On

Temporal Decoupling via Circadian Clock Resetbuilds_on (0.8)

Depended On By

Circadian Clock-Autophagy Synchronizationbuilds_on (1.0)Biorhythmic Interference via Controlled Sleep Oscillationsbuilds_on (0.6)Autophagosome Maturation Checkpoint Controlbuilds_on (0.6)Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulationbuilds_on (0.6)Transcriptional Autophagy-Lysosome Couplingbuilds_on (0.6)Circadian Glymphatic Rescue Therapy (Melatonin-focused)builds_on (0.6)Multi-Modal Stress Response Harmonizationbuilds_on (0.6)

Linked Experiments (10)

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.941 | neurodegeneration

Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction

Score: 0.933 | neurodegeneration

CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal

Score: 0.921 | neurodegeneration

Estimated Development

Estimated Cost

$15M

Timeline

4.5 years

🧪 Falsifiable Predictions (5)

5 total 0 confirmed 0 falsified

If hypothesis is true, intervention create a temporal amplification effect, substantially exceeding what might be achieved by constitutive autophagy stimulation

pending conf: 0.60

Expected outcome: create a temporal amplification effect, substantially exceeding what might be achieved by constitutive autophagy stimulation

Falsified by: Intervention fails to create a temporal amplification effect, substantially exceeding what might be achieved by constitutive autophagy stimulation

If hypothesis is true, intervention include two primary drug modalities

pending conf: 0.60

Expected outcome: include two primary drug modalities

Falsified by: Intervention fails to include two primary drug modalities

If hypothesis is true, intervention theoretically promote cancer cell survival in certain contexts)

pending conf: 0.60

Expected outcome: theoretically promote cancer cell survival in certain contexts)

Falsified by: Intervention fails to theoretically promote cancer cell survival in certain contexts)

If hypothesis is true, intervention reveal whether the former produces greater upregulation of additional autophagy genes (*ATG7*, *ATG5*, *BECN1*, *MAP1LC3B*) due to cooperative transactivation by endogenously high CLOCK-BMAL1 activity

pending conf: 0.60

Expected outcome: reveal whether the former produces greater upregulation of additional autophagy genes (*ATG7*, *ATG5*, *BECN1*, *MAP1LC3B*) due to cooperative transactivation by endogenously high CLOCK-BMAL1 activity

Falsified by: Intervention fails to reveal whether the former produces greater upregulation of additional autophagy genes (*ATG7*, *ATG5*, *BECN1*, *MAP1LC3B*) due to cooperative transactivation by endogenously high CLOCK-BMAL1 activity

If hypothesis is true, intervention employ **personalized dosing schedules** rather than fixed dosing times

pending conf: 0.60

Expected outcome: employ **personalized dosing schedules** rather than fixed dosing times

Falsified by: Intervention fails to employ **personalized dosing schedules** rather than fixed dosing times

Knowledge Subgraph (200 edges)

associated with (13)

NR3C1→neurodegenerationCRH→neurodegenerationTNFA→neurodegenerationPRKAA1→neurodegenerationULK1→neurodegeneration

▸ Show 8 more

DRD2→neurodegenerationSNCA→neurodegenerationPDGFRB→neurodegenerationANGPT1→neurodegenerationCHR2→neurodegenerationBDNF→neurodegenerationFOXP3→neurodegenerationTGFB1→neurodegeneration

co discussed (156)

BMAL1→CRHBMAL1→ULK1CLOCK→CRHCLOCK→ULK1CRH→BDNF

▸ Show 151 more

CRH→ULK1BDNF→ULK1BMAL1→TREM2TREM2→CLOCKTREM2→CRHTREM2→ULK1FOXP3→TNFAFOXP3→PPARGC1AFOXP3→PRKAA1FOXP3→NR3C1FOXP3→DRD2FOXP3→CHR2FOXP3→CLOCKFOXP3→CRHFOXP3→BDNFFOXP3→SNCAFOXP3→ANGPT1FOXP3→ULK1FOXP3→PDGFRBFOXP3→TGFB1TNFA→PPARGC1ATNFA→PRKAA1TNFA→NR3C1TNFA→DRD2TNFA→CHR2TNFA→CLOCKTNFA→CRHTNFA→BDNFTNFA→SNCATNFA→ANGPT1TNFA→ULK1TNFA→PDGFRBTNFA→TGFB1PPARGC1A→PRKAA1PPARGC1A→NR3C1PPARGC1A→DRD2PPARGC1A→CHR2PPARGC1A→CLOCKPPARGC1A→CRHPPARGC1A→BDNFPPARGC1A→SNCAPPARGC1A→ANGPT1PPARGC1A→ULK1PPARGC1A→PDGFRBPPARGC1A→TGFB1PRKAA1→NR3C1PRKAA1→DRD2PRKAA1→CHR2PRKAA1→CLOCKPRKAA1→CRHPRKAA1→BDNFPRKAA1→SNCAPRKAA1→ANGPT1PRKAA1→ULK1PRKAA1→PDGFRBPRKAA1→TGFB1NR3C1→DRD2NR3C1→CHR2NR3C1→CLOCKNR3C1→CRHNR3C1→BDNFNR3C1→SNCANR3C1→ANGPT1NR3C1→ULK1NR3C1→PDGFRBNR3C1→TGFB1DRD2→CHR2DRD2→CLOCKDRD2→CRHDRD2→BDNFDRD2→SNCADRD2→ANGPT1DRD2→ULK1DRD2→PDGFRBDRD2→TGFB1CHR2→CLOCKCHR2→CRHCHR2→BDNFCHR2→SNCACHR2→ANGPT1CHR2→ULK1CHR2→PDGFRBCHR2→TGFB1CLOCK→SNCACLOCK→ANGPT1CLOCK→PDGFRBCLOCK→TGFB1CRH→SNCACRH→ANGPT1CRH→PDGFRBCRH→TGFB1BDNF→SNCABDNF→ANGPT1BDNF→PDGFRBBDNF→TGFB1SNCA→ANGPT1SNCA→ULK1SNCA→PDGFRBSNCA→TGFB1ANGPT1→ULK1ANGPT1→PDGFRBANGPT1→TGFB1ULK1→PDGFRBULK1→TGFB1PDGFRB→TGFB1BACE1→JNKBACE1→P38JNK→P38JNK→TAUP38→TAUHSP70→HSP90C9ORF72→LRRK2IL10→TGFB1TGFB1→TNFCRH→BMAL1CRH→CLOCKULK1→CLOCKULK1→BDNFTREM2→BMAL1TREM2→SIRT1CRH→SIRT1BMAL1→SIRT1ULK1→SIRT1CLOCK→SIRT1CHR2→TNFACHR2→DRD2CHR2→PPARGC1ACHR2→PRKAA1CHR2→NR3C1PDGFRB→TNFAPDGFRB→CRHPDGFRB→SNCAPDGFRB→DRD2PDGFRB→ULK1PDGFRB→CLOCKPDGFRB→PPARGC1APDGFRB→PRKAA1PDGFRB→NR3C1PDGFRB→BDNFPDGFRB→ANGPT1CRH→DRD2CRH→PPARGC1ACRH→PRKAA1CRH→NR3C1SNCA→DRD2SNCA→CLOCKSNCA→PPARGC1ASNCA→PRKAA1SNCA→NR3C1SNCA→BDNFDRD2→PPARGC1A

interacts with (18)

NR3C1→CRHNR3C1→TNFACRH→NR3C1CRH→TNFATNFA→NR3C1

▸ Show 13 more

TNFA→CRHPPARGC1A→PRKAA1PRKAA1→PPARGC1ACLOCK→ULK1ULK1→CLOCKDRD2→SNCASNCA→DRD2PDGFRB→ANGPT1ANGPT1→PDGFRBCHR2→BDNFBDNF→CHR2FOXP3→TGFB1TGFB1→FOXP3

participates in (13)

NR3C1→Glucocorticoid receptor / stress responseCRH→Glucocorticoid receptor / stress responseTNFA→Glucocorticoid receptor / stress responsePRKAA1→PGC-1α / mitochondrial biogenesisULK1→Circadian clock / CLOCK-BMAL1 transcription

▸ Show 8 more

DRD2→Dopamine D2 receptor signalingSNCA→Dopamine D2 receptor signalingPDGFRB→Vascular / VEGF signalingANGPT1→Vascular / VEGF signalingCHR2→Hippocampal neurogenesis and synaptic plasticityBDNF→Hippocampal neurogenesis and synaptic plasticityFOXP3→TGF-β anti-inflammatory signalingTGFB1→TGF-β anti-inflammatory signaling

Mechanism Pathway for CLOCK/ULK1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    BDNF["BDNF"] -->|associated with| neurodegeneration["neurodegeneration"]
    SNCA["SNCA"] -->|associated with| neurodegeneration_1["neurodegeneration"]
    CRH["CRH"] -->|associated with| neurodegeneration_2["neurodegeneration"]
    TNFA["TNFA"] -->|associated with| neurodegeneration_3["neurodegeneration"]
    ULK1["ULK1"] -->|associated with| neurodegeneration_4["neurodegeneration"]
    TGFB1["TGFB1"] -->|associated with| neurodegeneration_5["neurodegeneration"]
    PPARGC1A["PPARGC1A"] -->|interacts with| PRKAA1["PRKAA1"]
    PRKAA1_6["PRKAA1"] -->|associated with| neurodegeneration_7["neurodegeneration"]
    PRKAA1_8["PRKAA1"] -->|interacts with| PPARGC1A_9["PPARGC1A"]
    NR3C1["NR3C1"] -->|associated with| neurodegeneration_10["neurodegeneration"]
    NR3C1_11["NR3C1"] -->|interacts with| CRH_12["CRH"]
    NR3C1_13["NR3C1"] -->|interacts with| TNFA_14["TNFA"]
    style BDNF fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style SNCA fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_1 fill:#ef5350,stroke:#333,color:#000
    style CRH fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_2 fill:#ef5350,stroke:#333,color:#000
    style TNFA fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_3 fill:#ef5350,stroke:#333,color:#000
    style ULK1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_4 fill:#ef5350,stroke:#333,color:#000
    style TGFB1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_5 fill:#ef5350,stroke:#333,color:#000
    style PPARGC1A fill:#ce93d8,stroke:#333,color:#000
    style PRKAA1 fill:#ce93d8,stroke:#333,color:#000
    style PRKAA1_6 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_7 fill:#ef5350,stroke:#333,color:#000
    style PRKAA1_8 fill:#ce93d8,stroke:#333,color:#000
    style PPARGC1A_9 fill:#ce93d8,stroke:#333,color:#000
    style NR3C1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_10 fill:#ef5350,stroke:#333,color:#000
    style NR3C1_11 fill:#ce93d8,stroke:#333,color:#000
    style CRH_12 fill:#ce93d8,stroke:#333,color:#000
    style NR3C1_13 fill:#ce93d8,stroke:#333,color:#000
    style TNFA_14 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 CLOCK — PDB 4F3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Digital biomarkers and AI-driven early detection of neurodegeneration

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)